Search results
Results from the WOW.Com Content Network
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
(Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian ...
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [5] [6] [11] [8] [12] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [6] and full approval in February 2023. [7]
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.
Nirogacestat was approved for medical use in the United States in November 2023. [2] It is the first medication approved by the US Food and Drug Administration (FDA) for the treatment of desmoid tumors. [2] [5] The FDA considers it to be a first-in-class medication. [6]
In 2021, the Food and Drug Administration approved Keytruda (pembrolizumab), an immunotherapy manufactured by Fortune 500 firm Merck, for post-surgical use in people with kidney cancer.
Irinotecan received accelerated approval from the US Food and Drug Administration (FDA) in 1996, [25] and full approval in 1998. [ 26 ] [ 27 ] [ 28 ] A liposome encapsulated version of irinotecan sold under the brand name Onivyde, was approved by the FDA in October 2015, to treat metastatic pancreatic cancer .